不同剂量阿司匹林在冠脉支架置入术后抗血小板的有效性及安全性  

The Efficacy and Safety of Aspirin in Antiplatelet for Coronary Stenting with Different Doses

作　　者：李涛[1] 陈永清[1] 梁素梅[1] 

机构地区：[1]兰州军区兰州总医院心血管内科,甘肃兰州730050

出　　处：《河北医学》2015年第2期207-210,共4页Hebei Medicine

基　　金：甘肃省兰州市科技局科研项目;(编号:2011-ZD-11)

摘　　要：目的:探讨不同剂量阿司匹林在冠脉支架置入术后抗血小板的有效性及安全性。方法:选择患者80例,分为两组,各40例,低剂量组采用阿司匹林100mg/d,高剂量组则采用阿司匹林300mg/d,比较两组患者治疗后肿瘤坏死因子-a、白细胞介素-6及超敏C反应蛋白水平,并统计两组发生临床死亡、再梗死率及脑卒中发生率,并分析异常出血情况。结果:治疗后高剂量组肿瘤坏死因子-a、超敏C反应蛋白及白细胞介素-6水平显著低于低剂量组(P<0.05),高剂量组发生临床死亡、再发心梗及脑卒中的比例显著低于低剂量组(P<0.05),高剂量组发生局部血肿、穿刺部位渗血、黑便、柏油样便及牙龈出血的比例显著低于低剂量组(P<0.05)。结论:冠状动脉介入术后使用300mg/d阿司匹林抗血小板,能有效降低机体炎症水平,预防心脑血管事件发生,且不增加出血相关并发症。Objective：To investigate the efficacy and safety of aspirin in antiplatelet for coronary stent-ing with different doses. Method：80 cases were divided into two groups, each with 40 cases,the low dose group was used 100mg/d, high dose group was used aspirin with 300mg/d, then patients after tumor necrosis factor -a, IL interleukin-6 and high-sensitivity C-reactive protein levels and abnormal bleeding statistical groups of clinical death, reinfarction and stroke incidence rates were compared in the two groups.Result：Af-ter treatment,tumor necrosis factor-a, levels of high-sensitivity C-reactive protein and interleukin-6 were significantly lower than low-dose group （P〈0.05）, clinical death occurred and the proportion of recurrent myocardial infarction and stroke in the high dose group were significantly lower than the low-dose group（ P〈0.05） , the high dose group with localized hematoma puncture site bleeding, black stools, tarry stools and gingival bleeding were significantly lower than the low dose group （ P〈0.05） . Conclusion：After coronary in-tervention use 300mg / d of aspirin antiplatelet can effectively reduce the level of inflammation, it can pre-vent cardiovascular events and,it is without increasing bleeding-related complications.

关 键 词：阿司匹林 冠脉支架置入术后 抗血小板 安全性 

分 类 号：R541.4[医药卫生—心血管疾病]